Table 1.
Patient characteristics. Data are presented as mean ± SD and as absolute numbers and percentages of category
| Godin: active (N = 332) | Godin: insufficiently active (N = 1108) | Total (N = 1440) | |
|---|---|---|---|
| Age (mean ± SD, min–max, median) | 63.3 ± 9.7 (36–88, 63) | 65.5 ± 10.4 (20–91, 66) | 65 ± 10.2 (20–91, 66) |
| BMI (mean ± SD, min–max, median) | 26.2 ± 4.7 (17.6–46.8, 25.2) | 26.7 ± 5.1 (14.4–54.4, 26) | 26.6 ± 5 (14.4–54.4, 25.8) |
| Time since diagnosis (years) (mean ± SD, min–max, median) | 9.0 ± 6.9 (0.2–39.1, 7.0) | 8.8 ± 6.9 (0.2–40.4, 7.0) | 8.9 ± 6.9 (0.2–40.4, 7.0) |
| TNM classification of the tumor at time of primary diagnosis—T, n (%) | |||
| X | 9 (2.8) | 66 (6.0) | 75 (5.3) |
| 1 | 95 (29.1) | 316 (28.7) | 411 (28.8) |
| 2 | 155 (47.4) | 450 (40.9) | 605 (42.4) |
| 3 | 38 (11.6) | 121 (11.0) | 159 (11.1) |
| 4 | 30 (9.2) | 148 (13.4) | 178 (12.5) |
| Missing | 5 | 7 | 12 |
| TNM tumor stadium at time of primary diagnosis—N, n (%) | |||
| X | 12 (3.7) | 101 (9.2) | 113 (7.9) |
| 0 | 103 (31.4) | 297 (27.0) | 400 (28.0) |
| 1 | 111 (33.8) | 384 (34.9) | 495 (34.6) |
| 2 | 54 (16.5) | 169 (15.3) | 223 (15.6) |
| 3 | 48 (14.6) | 150 (13.6) | 198 (13.9) |
| Missing | 4 | 7 | 11 |
| TNM tumor stadium at time of primary diagnosis—M, n (%) | |||
| X | 26 (8.0) | 91 (8.3) | 117 (8.2) |
| 0 | 224 (68.7) | 717 (65.2) | 941 (66.0) |
| 1 | 76 (23.3) | 292 (26.5) | 368 (25.8) |
| Missing | 6 | 8 | 14 |
| Grading, n (%) | |||
| G1 | 16 (5.1) | 50 (4.8) | 66 (4.8) |
| G2 | 222 (70.5) | 694 (66.2) | 916 (67.2) |
| G3 | 75 (23.8) | 303 (28.9) | 378 (27.7) |
| G4 | 2 (0.6) | 2 (0.2) | 4 (0.3) |
| Missing | 17 | 59 | 76 |
| Histological subtype, n (%) | |||
| Invasive ductal | 215 (67.2) | 744 (69.7) | 959 (69.1) |
| Invasive lobular | 65 (20.3) | 229 (21.5) | 294 (21.2) |
| Other subtypes | 40 (12.5) | 94 (8.8) | 134 (9.7) |
| Missing | 12 | 41 | 53 |
| Estrogen receptor, n (%) | |||
| Negative | 7 (2.1) | 23 (2.1) | 30 (2.1) |
| Positive | 324 (97.9) | 1084 (97.9) | 1408 (97.9) |
| Missing | 1 | 1 | 2 |
| Progesterone receptor, n (%) | |||
| Negative | 79 (23.9) | 255 (23.0) | 334 (23.2) |
| Positive | 249 (75.2) | 839 (75.8) | 1088 (75.7) |
| Unknown | 3 (0.9) | 13 (1.2) | 16 (1.1) |
| Missing | 1 | 1 | 2 |
| Metastases at primary diagnosis, n (%) | |||
| No | 270 (81.8) | 869 (78.9) | 1139 (79.5) |
| Yes | 60 (18.2) | 233 (21.1) | 293 (20.5) |
| Missing | 2 | 6 | 8 |
| Metastases localization, n (%) | |||
| Visceral metastases (lung, liver, CNS) | 130 (39.4) | 432 (39.1) | 562 (39.1) |
| Visceral and bone metastases | 65 (19.7) | 278 (25.1) | 343 (23.9) |
| Visceral without bone metastases | 65 (19.7) | 154 (13.9) | 219 (15.3) |
| Therapy line, n (%) | |||
| 1st line | 98 (29.5) | 310 (28.0) | 408 (28.3) |
| 2nd line | 111 (33.4) | 339 (30.6) | 450 (31.3) |
| 3rd line | 58 (17.5) | 217 (19.6) | 275 (19.1) |
| 4th line | 32 (9.6) | 122 (11.0) | 154 (10.7) |
| 5th line (and later) | 33 (9.9) | 120 (10.8) | 153 (10.6) |
| Prior antineoplastic surgery, n (%) | 309 (93.1) | 1011 (91.2) | 1320 (91.7) |
| Prior antineoplastic radiation, n (%) | 278 (83.7) | 897 (81.0) | 1175 (81.6) |